1. Rai K.R. Progress in chronic lymphocytic leukemia: a historical perspective // Baillieres Clin Hematol. 1993. Vol. 6. P. 757–765.
2. Gunz F.W. The dread leukemias and the lymphomas: their nature and their prospects // Blood, Pure and Eloquent / ed. M.M. Wintrobe. New York : McGraw Hill, 1980. P. 511–546.
3. Hamblin T. Historical aspects of chronic lymphocytic leukaemia // Br. J. Haematol. 2000. Vol. 111, N 4. P. 1023–1034.
4. Galton D.A.G. The Natural History of Chronic Lymphocytic Leukemia. Cambridge : Cambridge University, 1963.
5. Craigie D. Case of disease and enlargement of the spleen in which death took place from the presence of purulent matter in the blood // Edinb. Med. Surg. J. 1845. Vol. 64. P. 400–412.
6. Bennett J.H. Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood // Edinb. Med. Surg. J. 1845. Vol. 64. P. 413–423.
7. Bennett J.H. Leucocythemia or white cell blood // Relation to the Physiology and Pathology of the Lymphatic Glandular System. Edinburgh : Sutherland and Knox, 1852.
8. Virchow R. Weisses Blut // Neue Notizen aus dem Gebiete der Natur und Heilkunde. 1845. Bd 36. S. 151–156.
9. Einhorn M. Uber das Verhalten der Lymphocyten zu den weissen Blutkorperschen InauguralDissertat. Berlin, 1881.
10. Turk W. Ein System der Lymphomatosen // Klin. Wochenschr. 1903. Bd 16. S. 1073–1085.
11. Osler W. Leukaemia // Principles and Practice of Medicine. 7th ed. / ed. D. Appleton. New York, 1909. P. 731–738.
12. Minot G., Isaacs R. Lymphatic leukemia: age incidence, duration, and benefit derived from irradiation // Bost. Med. Surg. J. 1924. Vol. 191. P. 1–10.
13. Leavell B.S. Chronic leukemia: a study of incidence and factors influencing the duration of life // Am. J. Med. Sci. 1938. Vol. 196. P. 329–340.
14. Galton D.A.G. The pathogenesis of chronic lymphocytic leukaemia // Can. Med. Assoc. J. 1966. Vol. 94. P. 1005–1010.
15. Dameshek W. Chronic lymphocytic leukemia – an accumulative disease of immunologically incompetent lymphocytes // Blood. 1967. Vol. 29. P. 566–584.
16. Galton D.A.G. et al. Clinical trials of p(DI2chloroethylamino)phenylbutyric acid(CB 1348) in malignant lymphoma // Br. Med. J. 1955. Vol. 12. P. 1172–1176.
17. Shaw R.K. et al. A study of prednisone therapy in chronic lymphocytic leukemia // Blood. 1961. Vol. 17. P. 182–189.
18. Rai K.R., Sawitsky A., Cronkite E.P. Clinical staging of chronic lymphocytic leukemia // Blood. 1975. Vol. 46. P. 219–234.
19. Rai K.R. A critical analysis of staging in CLL // Chronic Lymphocytic Leukemia. Recent Progress and Future Directions / eds R.P. Gale, K.R. Rai. New York, 1987. P. 253–264.
20. Binet J.L., Leporrier M., Dighiero G. A clinical staging system for chronic lymphocytic leukemia // Cancer. 1977. Vol. 40. P. 855–864.
21. Binet J.L. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. Vol. 48, N 1. P. 198–206.
22. International Workshop on CLL. Chronic lymphocytic leukaemia: proposals for a revised staging system // Br. J. Haematol. 1981. Vol. 48. P. 365–367.
23. International Workshop on CLL. Recommendations for diagnosis, staging, and response criteria // Ann. Intern. Med. 1989. Vol. 110. P. 236–238.
24. Marti G.E., Zenger V. The natural history of CLL // Chronic Lymphocytic Leukemia. Totowa, NJ : Humana Press, 2004. P. 3–54.
25. Molica S. et al. Timing of diagnosis and lymphocyte accumulation patterns in chronic lymphocytic leukemia: analysis of their clinical significance // Eur. J. Haematol. 2009. Vol. 44, N 5. P. 277–281.
26. Zwiebel J.A., Cheson B.D. Chronic lymphocytic leukemia: staging and prognostic factors // Semin. Oncol. 1998. Vol. 25. P. 42–59.
27. Shen A. et al. Human heavychain variable region gene family nonrandomly rearranged in familial chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 1987. Vol. 84. P. 8563–8567.
28. Kipps T.J. et al. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 1989. Vol. 86, N 15. P. 5913–5917.
29. Damle R.N. et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia // Blood. 1999. Vol. 94. P. 1840–1847.
30. Stilgenbauer S., Lichter P., Dohner H. Genomic aberrations in BCLL chronic lymphocytic leukemia // Chronic Lymphoid Leukemias. 2nd ed. / ed. B.D. Cheson. New York : Marcel Dekker, 2001. P. 353–376.
31. Keating M.J., Kantarjian H., Talpaz M. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia // Blood. 1989. Vol. 74. P. 19–25.
32. Keating M.J. et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia // J. Clin. Oncol. 1991. Vol. 9, N 1. P. 44–49.
33. O’Brien S. et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysisderived prognostic model for response to treatment // Blood. 1993. Vol. 82, N 6. P. 1695–1700.
34. Rai K.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 24. P. 1750–1757.
35. Maloney D.G., Liles T.M., Czerwinski D.K. Phase I clinical trial using escalating singledose infusion of chimeric antiCD20 monoclonal antibody (IDECC2B8) in patients with recurrent Bcell lymphoma // Blood. 1994. Vol. 84. P. 2457–2466.
36. Maloney D.C., GrilloLopez A.J., White C.A. IDECC2B8 (rituximab) antiCD20 monoclonal antibody therapy in patients with relapsed lowgrade nonHodgkin’s lymphoma // Blood. 1997. Vol. 90. P. 2188–2195.